Sorry, you need to enable JavaScript to visit this website.
Home About Programs & Policies Grants Investigator Sponsored Research Anti-Infectives Areas of Interest

Anti-Infectives Areas of Interest

  • Ceftazidime-avibactam

    Research areas to be considered for support:

    • Microbiology and surveillance studies, invitro synergy studies with other antibiotics
    • Clinical efficacy 
    • Tissue penetration
    • Continuous infusion 

    Target populations:

    • ICU patients
    • Patients with comorbidities
    • Patients with previous antibiotic exposure in <6 months 
    • Recent hospitalization 

    Out of scope: 

    • Patients with confirmed gram positive infections

    Ceftaroline fosamil

    Research areas to be considered for support:

    • Activity vs. resistant pathogens;
    • Prevalence of resistant gram + pathogens (e.g., penicillin NS (non-susceptible), macrolide resistant and/or ceftriaxone resistant Streptococcus pneumoniae);
    • Monitor emergence of ceftaroline resistant strains: support local in vitro surveillance to supplement data;
    • Tissue penetration;
    • Bacteremia;
    • Severe community-acquired pneumonia (CAP) (incl. MRSA- methicillin resistant staphylococcus aureus);
    • Diabetic foot infections (DFI), surgical site infections (SSI) with complications (secondary osteo), resistant pathogens, pediatrics, meningitis, endocarditis, cystic fibrosis
  • Research areas to be considered for support:

    • Burden of Disease: Studies evaluating COVID-19 burden, healthcare resource utilization, direct and indirect costs and impact on QoL, specifically differentiating between high risk and non-high risk patients
    • Early Diagnosis and Patient Selection: Studies looking at making diagnostic pathways and patient selection for treatment more efficient, including biomarkers (for example, but not restricted to, quantifying viral load at diagnosis to assess relevance to predicting disease course or appropriateness for treatment)
    • Long COVID: Pathogenesis of and risk factors for Long COVID
    • Viral Rebound: Assessing associated symptoms and link to the occurrence of Long COVID
    • For nirmatrelvir; ritonavir specific studies:
      • Studies of nirmatrelvir; ritonavir in vaccinated/seropositive high risk patients
      • Benefits from combination of nirmatrelvir; ritonavir with other anti-virals (in key populations)
      • Studies looking at viral load reduction, immunity and impact on transmission rates with nirmatrelvir; ritonavir
      • Review of incidence of viral rebound across different treatments, including nirmatrelvir; ritonavir and no treatment
      • DDI management and impact on use of nirmatrelvir; ritonavir
      • Reasons for refusal of treatment of nirmatrelvir; ritonavir 
      • Reasons for incomplete treatment course of nirmatrelvir; ritonavir
  • Isavuconazole

    Research areas to be considered for support:

    • Improve awareness of invasive mold infections
    • Improve clinical diagnosis, new surrogate markers and diagnostic strategies, and improve mold infections laboratory capabilities
    • Isavuconazole real-world data. Experience using isavuconazole, epidemiology of IFI and health disparity opportunities. Use in ECMO, renal and hepatic dysfunction, and switch from other azoles
    • New uses for isavuconazole. prophylaxis, combination therapy, oral switch in candidiasis, in cryptococcus meningitis, and in chronic disease
    • Disparity and equity. Vulnerable populations or/and neglected diseases as well as supporting minority mycologists in low-income countries

    Target populations:

    • Hematological malignancy
    • Intensive care units
    • Emerging patients at risk such with influenza, covid19 and new chemotherapies
    • Chronic IFI disease and chronic pulmonary disease

    Out of scope:

    • Primary treatment of candidiasis
    • Endemic mycoses: All studies in endemic mycoses (HIV and crypto after animal model, cocci animal model)


    Invasive Fungal Infections Awareness and Diagnosis

    Research areas to be considered for support:

    • Improve awareness of invasive fungal infections (yeasts and molds)
    • Improve clinical diagnosis, new surrogate markers and diagnostic strategies, and improve invasive fungal infections (yeasts and molds) laboratory capabilities
      • use of diagnostic tools, images or other techniques to enhance the knowledge in the early diagnosis of invasive fungal infections